Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma

Judy Ahrar, Sanjay Gupta, Joe Ensor, Kamran Ahrar, David C. Madoff, Michael J. Wallace, Ravi Murthy, Alda Tam, Patrick Hwu, Agop Y. Bedikian

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

We reviewed the medical records of 42 patients with cutaneous melanoma metastatic to the liver who underwent hepatic artery chemoembolization (HACE) at our institution. HACE resulted in radiologic response (38.9) or disease stabilization (47.2) in most patients. The median overall survival (OS) and time to progression (TTP) of liver disease were 7.7 and 6 months, respectively. Patient's age, lactate dehydrogenase (LDH) levels, type of treatment, number of extrahepatic metastatic sites, and response to therapy were found to be significant predictors of OS after HACE. Prolonged survival was seen in patients who responded to HACE (p .034).

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalCancer Investigation
Volume29
Issue number1
DOIs
StatePublished - Jan 2011

Keywords

  • Cutaneous melanoma
  • Hepatic artery chemoembolization
  • Liver metastases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma'. Together they form a unique fingerprint.

Cite this